Drugs / SAR446597
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07215234 | Oct 2025 → Oct 2027 expected | diffuse secondary choroid atrophy | Sanofi | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-07-16 | Sanofi | Regulatory Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration sanofi.com ↗
The US Food and Drug Administration (FDA) has granted fast track designation to SAR446597, a one-time intravitreal gene therapy for the treatment of geographic atrophy (GA) due to age-related macular degeneration (AMD). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-07-16 | Sanofi | Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration sanofi.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR446597 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07215234 ↗ |
| Route | Intravitreal | “intravitreal injection” NCT07215234 ↗ |